Skip to main content

BioCardia, Inc. (BCDA)

NASDAQ: BCDA · IEX Real-Time Price · USD
1.88 -0.13 (-6.47%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap31.72M
Revenue (ttm)982,000
Net Income (ttm)-12.15M
Shares Out16.87M
EPS (ttm)-0.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume55,970
Open2.03
Previous Close2.01
Day's Range1.87 - 2.08
52-Week Range1.87 - 8.60
Beta1.70
AnalystsBuy
Price Target11.17 (+494.1%)
Earnings DateNov 9, 2021

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addit...

IndustryBiotechnology
CEOPeter Altman
Employees24
Stock ExchangeNASDAQ
Ticker SymbolBCDA
Full Company Profile

Financial Performance

In 2020, BioCardia's revenue was $145,000, a decrease of -79.58% compared to the previous year's $710,000. Losses were -$15.00 million, 2.01% more than in 2019.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BioCardia stock is "Buy" and the 12-month stock price forecast is 11.17.

Price Target
$11.17
(494.15% upside)
Analyst Consensus: Buy

News

BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

3 weeks ago - GlobeNewsWire

BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo...

3 weeks ago - GlobeNewsWire

Will BioCardia, Inc. (BCDA) Report Negative Q3 Earnings? What You Should Know

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulm...

1 month ago - GlobeNewsWire

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies

Technology Anticipated to Impact Cardiac Biologic Therapies, Transseptal Cardiac Procedures, and Other Interventional Catheter Based Therapies Technology Anticipated to Impact Cardiac Biologic Therapies...

1 month ago - GlobeNewsWire

BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial

SAN CARLOS, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulm...

1 month ago - GlobeNewsWire

BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Confe...

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular diseases...

1 month ago - GlobeNewsWire

CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Ann...

SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pu...

2 months ago - GlobeNewsWire

BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 20...

SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright 23r...

2 months ago - GlobeNewsWire

BioCardia to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, a...

3 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 4.76% and 72.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

3 months ago - GlobeNewsWire

Will BioCardia, Inc. (BCDA) Report Negative Q2 Earnings? What You Should Know

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies

SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise...

4 months ago - GlobeNewsWire

BioCardia to Be Added to the Russell Microcap® Index

SAN CARLOS, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today...

5 months ago - GlobeNewsWire

BioCardia to Present at the LD Micro Virtual Invitational Conference on June 8, 2021

SAN CARLOS, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, annou...

6 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Reports Q1 Loss, Tops Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 14.29% and 31.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

BioCardia Reports First Quarter 2021 Financial Results and Business Highlights

SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today ...

6 months ago - GlobeNewsWire

BioCardia Signs Agreement with Leading Japanese Biotechnology Company for Catheter Biotherapeutic Delivery Product Ca...

Second Biotherapeutic Partnership of 2021 Second Biotherapeutic Partnership of 2021

7 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 48.39% and -58.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

BioCardia Reports 2020 Financial Results and Recent Business Highlights

SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative therapies, to...

8 months ago - GlobeNewsWire

BioCardia to Present at Maxim Group's Inaugural Emerging Growth Virtual Conference

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that C...

8 months ago - GlobeNewsWire

BioCardia Announces Clinical Leadership Changes

SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced c...

9 months ago - GlobeNewsWire

BioCardia Update on Cell Therapy Product Development and 2021 Milestones

SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an ...

10 months ago - GlobeNewsWire

Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia's Board of Directors

SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Krisztin...

10 months ago - GlobeNewsWire